October 12, 2026
Good morning, everyone. Grab a seat because the coffee's hot and the market's on fire. Today we've got it all: Brazil shining, oil climbing, Musk stirring things up in telecom, and China flexing its muscles in robotics. Let's get to what matters.
---The fact: The Brazilian stock market is in breakout mode, driven by expectations surrounding the presidential election, attracting investors looking to escape excessive concentration in US tech stocks.
Verdict: I'd Buy. Foreign flows are coming back and Brazil's valuation is still discounted. When the world turns its gaze this way, the wind works in your favor.
Assets and sectors: EWZ (Brazil ETF), PETR4, VALE3, ITUB4.
The fact: Houthi attacks on Saudi Arabia have raised alarms over global energy supply, pushing oil higher on the eve of inflation data and central bank commentary.
Verdict: I'd Buy. Geopolitics in the Middle East is pure gasoline for Brent. As long as the risk persists, the risk premium stays baked into the price.
Assets and sectors: Brent, WTI, XOM, PETR4.
The fact: Starlink closed an $8 billion deal to buy spectrum in the US and make its full entry into the mobile phone market, dragging down shares of Verizon, AT&T, and T-Mobile.
Verdict: I'd Reduce exposure to traditional US telcos. Musk doesn't play around and he's coming to cannibalize margins. I'd rather stay out until the dust settles.
Assets and sectors: VZ, T, TMUS, telecom sector.
The fact: MAtek, a Taiwanese semiconductor testing company, hit a revenue record for the seventh consecutive month, with 12.31% year-over-year growth in September.
Verdict: I'd Hold my position in the sector. The semiconductor cycle remains hot and demand for testing only grows with AI and data centers.
Assets and sectors: TSM, NVDA, SOXX, semiconductor sector.
The fact: Unitree, a Chinese robot manufacturer, drew 5,500 times more demand than supply in its IPO in China, raising $900 million and igniting interest in robotics and AI.
Verdict: I'd Hold my position in robotics and automation. Chinese retail appetite is a thermometer for what's coming. It's not time to sell, but it's also not time to buy just anything.
Assets and sectors: BOTZ, ROBO, industrial automation sector.
The fact: Anvisa has authorized human trials for a groundbreaking malaria vaccine developed in Brazil, targeting the most common parasite in the country.
Verdict: I'd Hold my position in Brazilian health care. It's positive long-term news, but still in early stages. It doesn't change the investment thesis today.
Assets and sectors: FLRY3, HAPV3, health care and biotech sector.
EWZ and local blue chips.Brent and PETR4 on the radar.TSM and SOXX remain structural bets.BOTZ is a diversified entry point.VZ, T, and TMUS.Sources: Biztoc, InfoMoney, O Globo, Digitimes,
Biztoc.com
Brazilian stocks are breaking out as investors look for opportunities beyond tech
Ivar recommends Swissquote bank for your international investments. By opening your account through the link below and trading 5 lots or more, you will receive $200 to use on Ivar AI and activate your subscription. Take advantage of this exclusive offer available today!
Offer available for you who have not yet opened your account at Swissquote.
Services available globally except for the following countries: Algeria, Belgium, Canada, China, North Korea, USA, France, Hong Kong, Iran, Iraq, Nigeria, Singapore, Syria, Turkey and Zimbabwe.